Yun-Feng Zhao1, Yong Lin, Wei-Guo Zhang. 1. Department of Respiratory Disease, Zhongda Hospital, Southeast University, Nanjing 210009, China. Email: yfzh71@yahoo.com.cn.
Abstract
OBJECTIVE: To study the clinical significance of serum copeptin in patients with community-acquired pneumonia (CAP). METHODS: Sixty-two cases of hospitalized CAP including 32 males and 30 females with a mean age of (45 +/- 25) years were recruited from the respiratory wards in the affiliated Zhongda Hospital of Southeast University from March 2009 to June 2009. Sixteen healthy volunteers including 8 males and 8 females with a mean age of (41 +/- 23) years served as the control. The CAP patients were divided into 3 groups: grade I - III (n = 24), grade IV (n = 20) and grade V (n = 18) according to pneumonia severity index (PSI). Serum copeptin, blood routine, serum high-sensitivity C-reactive protein, arterial partial pressure of oxygen (PaO2) and oxygenation index (PaO2/FiO2) were detected in the patients with CAP before and after the treatment as well as the volunteers in the control group. The difference of related data among 4 groups were compared. q test was adopted in the comparison between the groups, and group paired t test was adopted in the comparison between parameters before and after the treatment. RESULTS: Serum copeptin concentration of the grade V patients [(0.91 +/- 0.16) microg/L] was significantly higher than those of thegrade IV patients [(0.56 +/- 0.11) microg/L], grade I - III patients [(0.34 +/- 0.06) microg/L] and the control group [(0.08 +/- 0.02) microg/L] before the treatment. Serum copeptin concentration of the grade V patients [(0.11 +/- 0.04) microg/L], grade IV patients [(0.13 +/- 0.05) microg/L], and grade I - III patients [(0.07 +/- 0.03) microg/L] after the treatment were significantly lower than those before the treatment. Serum high-sensitivity C-reactive protein and the total number of white blood cells of the patients with CAP were significantly higher than those of the control group before the treatment. Serum high-sensitivity C-reactive protein and total number of white blood cells of the patients with CAP were significantly decreased after the treatment. PaO2 and PaO2/FiO2 of the grade V patients were significantly lower than those of the grade IV patients, grade I - III patients and the control group before the treatment, and were significantly increased after the treatment. CONCLUSION: Serum copeptin could be used as an inflammatory marker for judging the treatment efficacy in patients with CAP.
OBJECTIVE: To study the clinical significance of serum copeptin in patients with community-acquired pneumonia (CAP). METHODS: Sixty-two cases of hospitalized CAP including 32 males and 30 females with a mean age of (45 +/- 25) years were recruited from the respiratory wards in the affiliated Zhongda Hospital of Southeast University from March 2009 to June 2009. Sixteen healthy volunteers including 8 males and 8 females with a mean age of (41 +/- 23) years served as the control. The CAP patients were divided into 3 groups: grade I - III (n = 24), grade IV (n = 20) and grade V (n = 18) according to pneumonia severity index (PSI). Serum copeptin, blood routine, serum high-sensitivity C-reactive protein, arterial partial pressure of oxygen (PaO2) and oxygenation index (PaO2/FiO2) were detected in the patients with CAP before and after the treatment as well as the volunteers in the control group. The difference of related data among 4 groups were compared. q test was adopted in the comparison between the groups, and group paired t test was adopted in the comparison between parameters before and after the treatment. RESULTS: Serum copeptin concentration of the grade V patients [(0.91 +/- 0.16) microg/L] was significantly higher than those of thegrade IV patients [(0.56 +/- 0.11) microg/L], grade I - III patients [(0.34 +/- 0.06) microg/L] and the control group [(0.08 +/- 0.02) microg/L] before the treatment. Serum copeptin concentration of the grade V patients [(0.11 +/- 0.04) microg/L], grade IV patients [(0.13 +/- 0.05) microg/L], and grade I - III patients [(0.07 +/- 0.03) microg/L] after the treatment were significantly lower than those before the treatment. Serum high-sensitivity C-reactive protein and the total number of white blood cells of the patients with CAP were significantly higher than those of the control group before the treatment. Serum high-sensitivity C-reactive protein and total number of white blood cells of the patients with CAP were significantly decreased after the treatment. PaO2 and PaO2/FiO2 of the grade V patients were significantly lower than those of the grade IV patients, grade I - III patients and the control group before the treatment, and were significantly increased after the treatment. CONCLUSION: Serum copeptin could be used as an inflammatory marker for judging the treatment efficacy in patients with CAP.